Yu-Ning Wong
About
Yu-Ning Wong is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Surgery.
According to data from OpenAlex, Yu-Ning Wong has authored 30 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Economics and Econometrics and 8 papers in Surgery. Recurrent topics in Yu-Ning Wong's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Economic and Financial Impacts of Cancer (6 papers). Yu-Ning Wong is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Economic and Financial Impacts of Cancer (6 papers). Yu-Ning Wong collaborates with scholars based in United States, Spain and Italy. Yu-Ning Wong's co-authors include Jorge A. García, Daniel H. Shevrin, Manish Kohli, Maha Hussain, Robert S. DiPaola, Christopher J. Sweeney, Glenn Liu, Yu‐Hui Chen, Noah M. Hahn and Joel Picus and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.
In The Last Decade
Yu-Ning Wong
30 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yu-Ning Wong United States | 21 | 2.2k | 954 | 810 | 662 | 521 | 30 | 3.2k | ||
| D. Scott Ernst Canada | 30 | 2.8k 1.3× | 1.8k 1.8× | 767 0.9× | 529 0.8× | 925 1.8× | 77 | 4.3k | ||
| R. Bryan Rumble United States | 32 | 2.5k 1.1× | 2.1k 2.2× | 923 1.1× | 511 0.8× | 896 1.7× | 68 | 4.3k | ||
| A. Rodrı́guez-Antolı́n Spain | 18 | 2.5k 1.1× | 634 0.7× | 665 0.8× | 782 1.2× | 388 0.7× | 142 | 3.2k | ||
| C.A. Lawton United States | 34 | 5.2k 2.4× | 680 0.7× | 469 0.6× | 819 1.2× | 831 1.6× | 132 | 6.2k | ||
| D.A. Loblaw Canada | 29 | 2.5k 1.1× | 587 0.6× | 306 0.4× | 487 0.7× | 643 1.2× | 88 | 3.4k | ||
| James J. Dignam United States | 24 | 1.0k 0.5× | 1.8k 1.8× | 1.2k 1.5× | 270 0.4× | 353 0.7× | 55 | 3.5k | ||
| Adolfo Favaretto Italy | 31 | 2.2k 1.0× | 1.7k 1.8× | 357 0.4× | 231 0.3× | 335 0.6× | 136 | 3.7k | ||
| John Staffurth United Kingdom | 31 | 2.8k 1.3× | 1.1k 1.1× | 885 1.1× | 1.2k 1.8× | 765 1.5× | 117 | 4.4k | ||
| Michael Häggman Sweden | 20 | 3.6k 1.6× | 992 1.0× | 404 0.5× | 313 0.5× | 975 1.9× | 54 | 4.3k | ||
| William T. Lowrance United States | 36 | 2.4k 1.1× | 744 0.8× | 381 0.5× | 431 0.7× | 1.5k 2.8× | 116 | 4.0k |
Countries citing papers authored by Yu-Ning Wong
Since
Specialization
Citations
This map shows the geographic impact of Yu-Ning Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu-Ning Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu-Ning Wong more than expected).
Fields of papers citing papers by Yu-Ning Wong
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yu-Ning Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu-Ning Wong. The network helps show where Yu-Ning Wong may publish in the future.
Co-authorship network of co-authors of Yu-Ning Wong
This figure shows the co-authorship network connecting the top 25 collaborators of Yu-Ning Wong. A scholar is included among the top collaborators of Yu-Ning Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu-Ning Wong. Yu-Ning Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jayadevappa, Ravishankar, Sumedha Chhatre, Joseph J. Gallo, et al.. (2019). Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology. 37(12). 964–973.
2.
Jayadevappa, Ravishankar, Sumedha Chhatre, Yu-Ning Wong, et al.. (2017). Comparative effectiveness of prostate cancer treatments for patient-centered outcomes. Medicine. 96(18). e6790–e6790.
3.
Wong, Yu-Ning, Judith Manola, Gary R. Hudes, et al.. (2017). Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clinical Genitourinary Cancer. 16(2). e315–e322.
4.
Rini, Brian I., Tanya B. Dorff, Paul Elson, et al.. (2016). Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. The Lancet Oncology. 17(9). 1317–1324.
5.
Kircher, Sheetal, Halla Nimeiri, Daniel M. Geynisman, et al.. (2015). The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?. Value in Health. 19(1). 88–98.
6.
Hoffman‐Censits, Jean & Yu-Ning Wong. (2015). Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma. Clinical Genitourinary Cancer. 13(4). 302–308.
7.
Tseng, Yolanda D., Hajime Uno, Melissa E. Hughes, et al.. (2015). Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. International Journal of Radiation Oncology*Biology*Physics. 93(3). 622–630.
8.
Sweeney, Christopher J., Yu‐Hui Chen, Michael A. Carducci, et al.. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine. 373(8). 737–746.
9.
Sonpavde, Guru, Joaquim Bellmunt, Jonathan E. Rosenberg, et al.. (2014). Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 12(6). 395–398.
10.
Sonpavde, Guru, Gregory R. Pond, Jonathan E. Rosenberg, et al.. (2014). Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer. 13(2). 185–192.
11.
Plimack, Elizabeth R., Jean Hoffman‐Censits, Rosalia Viterbo, et al.. (2014). Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. Journal of Clinical Oncology. 32(18). 1895–1901.
12.
Smaldone, Marc C., Elizabeth A. Handorf, Simon P. Kim, et al.. (2014). Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database. The Journal of Urology. 193(4). 1108–1113.
13.
Dotan, Efrat, Tianyu Li, Michael J. Hall, et al.. (2014). Oncologists' Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. Journal of Oncology Practice. 10(5). 308–314.
14.
Wong, Yu-Ning, Brian L. Egleston, Tammy K. Stump, et al.. (2013). Cancer Patients’ Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting. Medical Care. 51(9). 838–845.
15.
Manne, Sharon L., Deborah A. Kashy, Terrance L. Albrecht, et al.. (2013). Knowledge, Attitudes, and Self-efficacy as Predictors of Preparedness for Oncology Clinical Trials. Medical Decision Making. 34(4). 454–463.
16.
Pollack, Craig Evan, Justin E. Bekelman, Andrew J. Epstein, et al.. (2011). Racial Disparities in Changing to a High-volume Urologist Among Men With Localized Prostate Cancer. Medical Care. 49(11). 999–1006.
17.
Dominici, Laura S., Julie Najita, Melissa E. Hughes, et al.. (2011). Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Research and Treatment. 129(2). 459–465.
18.
Canter, Daniel, Rosalia Viterbo, Alexander Kutikov, et al.. (2010). Baseline Renal Function Status Limits Patient Eligibility to Receive Perioperative Chemotherapy for Invasive Bladder Cancer and Is Minimally Affected by Radical Cystectomy. Urology. 77(1). 160–165.
19.
Romanus, Dorothy, Martin R. Weiser, John M. Skibber, et al.. (2009). Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: An NCCN Institutional Analysis. Journal of the National Comprehensive Cancer Network. 7(8). 895–904.
20.
Wong, Yu-Ning, Nandita Mitra, Gary R. Hudes, et al.. (2006). Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men. JAMA. 296(22). 2683–2683.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by D. Scott Ernst Breakdown of academic impact, for papers by R. Bryan Rumble Breakdown of academic impact, for papers by A. Rodrı́guez-Antolı́n Breakdown of academic impact, for papers by C.A. Lawton Breakdown of academic impact, for papers by D.A. Loblaw Breakdown of academic impact, for papers by James J. Dignam Breakdown of academic impact, for papers by Adolfo Favaretto Breakdown of academic impact, for papers by John Staffurth Breakdown of academic impact, for papers by Michael Häggman Breakdown of academic impact, for papers by William T. Lowrance